| Interactions between Xenobiotics and DME (XEOTIC)
|
| Health or Environmental Toxicant(s) |
| Health Hazard/Toxicant |
Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
|
| Diethylhexyl phthalate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01004
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Health Hazard |
| DME Modulation |
Diethylhexyl phthalate inhibits the expression of DME GSTO2 |
[1] |
| Tris(1,3-dichloro-2-propyl)phosphate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01031
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Health Hazard |
| DME Modulation |
Tris(1,3-dichloro-2-propyl)phosphate up-regulates the expression of DME GSTO2 |
[2] |
| Natural Product(s), Extract(s) or Medicine(s) |
| Traditional Medicine |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Jinfukang |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00760
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Traditional Medicine |
| DME Modulation |
Jinfukang up-regulates the expression of DME GSTO2 |
[3] |
| Pharmaceutical Agent(s) |
| Approved/Marketed Drug |
Click to Show/Hide the Full List of Xenobiotics: 4 Xenobiotics
|
| Amiodarone hydrochloride |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00277
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Amiodarone hydrochloride up-regulates the expression of DME GSTO2 |
[4] |
| Copper sulfate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00117
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Copper sulfate inhibits the expression of DME GSTO2 |
[5] |
| Urethane |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00435
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Urethane inhibits the drug-metabolizing activity of DME GSTO2 |
[6] |
| Valproic acid |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00029
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Valproic acid induces the drug-metabolizing activity of DME GSTO2 |
[7] |
| Drug in Phase 2 Clinical Trial |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| MS-275 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00581
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
MS-275 up-regulates the expression of DME GSTO2 |
[8] |
| Preclinical/Patented Drug |
Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
|
| ICG-001 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01336
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Patented Pharmaceutical Agent |
| DME Modulation |
ICG-001 up-regulates the expression of DME GSTO2 |
[9] |
| K-7174 |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01348
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Patented Pharmaceutical Agent |
| DME Modulation |
K-7174 inhibits the expression of DME GSTO2 |
[10] |
|
|
|
|
|
|